Mendus

Mendus AB is a clinical-stage biopharmaceutical company focused on developing immunotherapies to address tumor recurrence and established hard-to-treat tumors. Mendus is leveraging our unparalleled expertise in allogeneic dendritic cell biology to advance a clinical pipeline featuring novel, off-the-shelf, cell-based immunotherapies that combine clinical efficacy with a favorable safety profile.